• Disciplinary proceedings opened against Croatian Football Federation
  
• Fowl Ball” Could Be A Huge Hit For Young Sluggers
  
• New Chief Executive of the Meat Hygiene Service appointed
  
• Sale of British Airways Travel Clinic
  
• Lufthansa resumes flights to Beirut
  
• Partnership for Change with Air Navigation Service Providers, Cost Efficiency, Environment
  
• Head-to-head study comparing Lexiva® to Kaletra presented at IAC 2006 and published in The Lancet
  
• Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant TM
  
• Medicines, money and motivated health workers are key...
  
• Skindividual preserve skin’s youthful beauty
  
• A weekend in Paris
  
• Fifth Annual EA Sports Madden Challenge Starts September 1st to...
  
• Akamai and Instant Media Team to Deliver Seamless High-Definition Internet Video Experience
  
• Teva Announces Launch of Generic Zoloft®
  
• Zoller Wine Styling Offers Custom Made Premium Winemaking
  

Medtronic Announces Offer of Senior Notes Due 2010 and 2015

Medtronic, Inc. (NYSE: MDT) announced today that it has priced an offering of $400 million aggregate principal amount of 4.375 percent notes due 2010 and $600 million aggregate principal amount of 4.75 percent notes due 2015.

Medtronic intends to use the net proceeds from the sale of the notes for general corporate purposes, including the repayment of a portion of its outstanding commercial paper.

The notes are being offered in the United States to qualified institutional buyers, pursuant to Rule 144A under the Securities Act of 1933, as amended, and outside of the United States in reliance on Regulation S under the Securities Act. The notes have not been registered under the Securities Act and may not be offered or sold in the United States without registration or an applicable exemption of the registration requirements.

Each series of notes will be Medtronic’s general unsecured senior obligations and will rank equally in right of payment with its existing and future unsubordinated debt, but will be structurally subordinated to all future and existing obligations of Medtronic’s subsidiaries. The notes will be redeemable at any time prior to their respective maturities at prices equal to the greater of the principal amount thereof and the sum of the present values of the remaining scheduled payments of principal and interest in respect of the notes to be redeemed discounted to the date of redemption, plus, in each case, accrued interest.

Medtronic has agreed, subject to certain restrictions and conditions, to file with the Securities and Exchange Commission an exchange offer registration statement or, under certain circumstances, a shelf registration statement, pursuant to a registration rights agreement.

Medtronic Inc.

• Medtronic Marks Sale of 1 Millionth CapSureFix® Novus Model 5076 Cardiac Pacing Lead
  
• Neurology Academy Upgrades Deep Brain Stimulation In Latest Parkinson s Treatment Guidelines
  
• Medtronic Announces FDA Approval of Expanded Labeling for Its Cardiac Resychronization Therapy CRT
  
• Medtronic To Participate In The Bear Stearns London Healthcare Conference
  
• Medtronic Sues Biomet And EBI Spine For Patent Infringement
  
• Medtronic Breaks Ground On New Cardiac Rhythm Management Headquarters
  
• Medtronic Submits First PMA Module For Talent Thoracic Stent Graft System
  
• Medtronic Announces Offer of Senior Notes Due 2010 and 2015
  
• New Study Results Show Cardiac Resynchronization Therapy Saves Many Lives...
  
• Medtronic Implantable Heart Monitor Reduces Recurrence of Fainting